RevealDx partners with 4DMedical to expand AI lung cancer diagnostics globally

RevealDx has signed a distribution agreement with 4DMedical and secured a $3.4 million strategic investment to expand global access to its AI-powered RevealAI-Lung platform. Under the agreement, 4DMedical will distribute the FDA-cleared, MDR-certified, and TGA-approved technology across the US, Europe, Australia, and New Zealand.

As an executive search partner to the MedTech industry, Guided Solutions keeps a close eye on stories like this one. Subscribe to our Industry Insights for weekly coverage.

RevealAI-Lung uses AI to assess incidental lung nodules by generating a malignancy similarity score, helping radiologists improve cancer risk assessment and clinical decision-making. The platform has been validated on more than 1,500 patients and is already integrated into 4DMedical's recently acquired contextflow platform at several European clinical sites.

“We are excited to announce our new partnership with 4DMedical,” said Chris Wood, CEO of RevealDx. “The resources they bring will expand our reach and help clinicians identify potentially malignant lung nodules earlier and with greater confidence, ultimately benefiting more patients.”